Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis

Authors

  • L. Poluben National Research Center for Radiation Medicine, Kyiv 02000, Ukraine
  • Ch.R. Bryke Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA
  • Y. Hsu Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA
  • O. Shumeiko Bogomolets National Medical University
  • L. Neumerzhitska National Research Center for Radiation Medicine, Kyiv 02000, Ukraine
  • B. Klimuk National Research Center for Radiation Medicine, Kyiv 02000, Ukraine
  • L. Rybchenko National Research Center for Radiation Medicine, Kyiv 02000, Ukraine
  • S. Klymenko National Research Center for Radiation Medicine, Kyiv 02000, Ukraine
  • S.P. Balk Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA
  • P.G. Fraenkel Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston 02215, MA, USA

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12540

Keywords:

copy number alterations, copy-neutral loss of heterozygosity, driver mutation, primary myelofibrosis

Abstract

Summary. Aim: To examine frequencies and spectrum of genomic alterations in Ukrainian patients diagnosed with primary myelofibrosis (PMF). Materials and Methods: We enrolled 30 Ukrainian patients diagnosed with PMF who were previously tested for usual mutations in mye­loproliferative neoplasms driver genes (JAK2, MPL and CALR). Genomic DNA samples were obtained from peripheral blood leukocytes of these patients. Copy number alterations and copy-neutral loss of heterozygosity (cnLOH) were assessed using a high-density CytoScan HD microarray platform. Statistical significance was evaluated by the Fisher exact test. Results: We identified frequent genomic alterations, but no significant difference in the rates of copy-number loss, copy-number gain, cnLOH, or multiple genomic alterations were found in the groups of PMF patients that were positive for one of the usual mutations in driver genes or negative for such mutations (33.3% and 55.6%, p = 0.4181, 19.0% and 11.1%, p = 1.0000, 61.9% and 44.4%, p = 0.4434, 33.3% and 55.6%, p = 0.4181, respectively). The most frequent alterations were cnLOH at 1p36-1p22, 9p24.3-9p13.3 and 11q12.3-11q25; copy number loss at 7q21-7q36.3 and 13q12.3-13q14.3. Copy number alterations and cnLOH commonly affected the EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53 genes, in addition to JAK2, MPL and CALR. Conclusion: We demonstrated the spectrum of genomic alterations in the groups of the Ukrainian PMF patients with or without the usual mutations in the specific driver genes. We identified several potential genes, which may be involved in the myeloproliferative neoplasms development and their phenotype modification (EZH2, LAMB4, CBL, CUX1, ATM, RB1 and TP53).

References

Shantzer L, Berger K, Pu JJ. Primary myelofibrosis and its targeted therapy. Ann Hematol 2017; 96: 531–5.

Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 2016; 127: 325–32.

Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118: 167–76.

Rice KL, Lin X, Wolniak K, et al. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J 2011; 1: e40.

Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129: 680–92.

Tefferi A, Sirhan S, Sun Y, et al. Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2 V617F mutational status and conventional chromosome analysis. Leuk Res 2009; 33: 662–4.

Poluben L, Puligandla M, Neuberg D, et al. Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. Am J Hematol 2019; 94: 62–73.

Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119: 1208–13.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, et al. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol 2012; 91: 533–41.

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017; 129: 667–79.

Aranaz P, Hurtado C, Erquiaga I, et al. CBL mutations in myeloproliferative neoplasms are also found in the gene’s proline-rich domain and in patients with the V617FJAK2. Haematologica 2012; 97: 1234–41.

McClure RF, Ewalt MD, Crow J, et al. Clinical significance of DNA variants in chronic myeloid neoplasms (CMNs): A report of the association for molecular pathology. J Mol Diagnostics 2018; 20: 717–37.

Wang L, Xiao H, Zhang X, et al. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol 2014; 7: 61.

Tefferi A, Lasho T, Begna K, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908–19.

Downloads

Published

08.06.2023

How to Cite

Poluben, L., Bryke, C., Hsu, Y., Shumeiko, O., Neumerzhitska, L., Klimuk, B., … Fraenkel, P. (2023). Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis. Experimental Oncology, 41(1), 53–56. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-1.12540

Issue

Vol. 41 No. 1 (2019): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.